SEP 14, 2020 9:00 AM PDT

Direct Amplification: Rapid, Extraction-Free RT-qPCR Results

SPONSORED BY: Promega Corporation

As the SARS-CoV-2 pandemic continues to rage across the United States and around the globe, the demand for COVID-19 testing is increasing. The vast majority of the COVID-19 assays use RT-qPCR to detect the viral RNA in patient samples such as nasopharyngeal swabs, which are collected and stored in viral or universal transport media (VTM/UTM). The general workflow for these COVID-19 assays can be broken down as follows: 

  1. Collect and store patient samples

  2. Ship samples to testing laboratory

  3. Extract RNA from samples

  4. Amplify and analyze samples 

While many companies who manufacture the products that are used in these steps have been able to adapt and significantly increase their production capacities, there are still gaps between the supply of these products and the global test demand. Both the sample collection and storage step and the RNA extraction/purification step have a tendency to bottleneck and experience supply constraints.

One way to address these bottlenecks and expand production capacity for these in-demand products is to evaluate the viability of skipping a step in the workflow, without hindering the ability to detect viral RNA from samples. A direct amplification method, that simplifies and accelerates time to qPCR results, is a good solution to bypass the particularly rate-limiting step of RNA extraction.

As the name implies, direct PCR is a method that enables direct PCR amplification of a sample without prior RNA or DNA extraction and purification steps. By removing those more time-consuming steps, you can complete the upstream process more quickly, enabling you to move on to the downstream processing faster. 

Challenges in Direct Amplification 

Direct PCR amplification comes with its own set of challenges. As with any PCR assay, PCR inhibition is always a factor for consideration. PCR inhibitors—from both the sample and the lysis buffer utilized to lyse and release the RNA—have the potential to skew quantification in qPCR. In a typical PCR workflow, the solution to PCR inhibition is to purify or dilute the RNA extracts, which leads to a loss of RNA. Since direct amplification skips the purification step, it is helpful to have an understanding of underlying molecular inhibition mechanisms to help overcome any analytical limitations that you may experience in the presence of PCR inhibitors.

The second main challenge to overcome in direct PCR amplification is assay sensitivity. Prior to analysis, RNA extraction can serve as a concentrating step, usually beginning with Xµl of VTM and eluting in Yµl—resulting in a Z-fold increase in the sample concentration going into the RT-qPCR assay. In direct amplification, there is no sample concentration. In fact, you are usually going to dilute the sample during the lysis step to release the RNA. To overcome this, you many need to re-optimize your PCR assay, given that a PCR assay that is optimized to amplify extracted RNA may not be optimized for a direct-from-sample amplification.

Benefits of Direct Amplification 

Despite its challenges, there are many benefits to direct PCR amplification. In a typical PCR workflow, the extraction and purification wash steps utilize many buffers and optimization reagents. In a direct amplification workflow, you are able to circumvent these costly and rate-limiting steps, allowing you to avoid potential throughput limitations from reagent supply constraint and enabling you to cut costs and conserve precious sample material. Utilizing a direct PCR workflow additionally helps save you time in the lab, though the amount of time savings will vary depending on if your previous RNA extraction method was automated or manual. Direct amplification workflows are also automation-friendly, requiring no dependency on specially-designed plastic consumables. 

Learn more about direct PCR amplification solutions and how they can be customized to fit your needs.

About the Sponsor
  • With a portfolio of more than 4,000 products covering the fields of genomics, protein analysis and expression, cellular analysis, drug discovery and genetic identity, Promega is a global leader in providing innovative solutions and technical support to life scientists in academic, industrial and government settings.
You May Also Like
JAN 26, 2021
Genetics & Genomics
Why Only Some People With a Rare Mutation Get a Heart Condition
JAN 26, 2021
Why Only Some People With a Rare Mutation Get a Heart Condition
Scientists have found a way to explain why a heart condition called hypertrophic cardiomyopathy (HCM) can be so differen ...
JAN 31, 2021
Microbiology
Does a Strain of Gut Bacteria Cause Parental Neglect?
JAN 31, 2021
Does a Strain of Gut Bacteria Cause Parental Neglect?
The gut microbiome is made up of a huge number of different microbial species, and scientists are learning more about ho ...
FEB 02, 2021
Cell & Molecular Biology
Muscle Cells Can Block Inflammation When Exercised
FEB 02, 2021
Muscle Cells Can Block Inflammation When Exercised
Inflammation can be a crucial process; the body needs it to heal injuries and prevent infection. But inflammatory proces ...
FEB 22, 2021
Genetics & Genomics
Some People Can Tolerate Cold Weather Because of a Gene Variant
FEB 22, 2021
Some People Can Tolerate Cold Weather Because of a Gene Variant
Some people just aren't that bothered by cold weather; can it be their genes? New work has suggested that when humans be ...
FEB 24, 2021
Health & Medicine
CBG and CBD Cannabinoids Show Worth in Thwarting Glioblastoma Tumors
FEB 24, 2021
CBG and CBD Cannabinoids Show Worth in Thwarting Glioblastoma Tumors
With the average length of survival following diagnosis being only 16 months, a glioblastoma — malignant tumor aff ...
FEB 25, 2021
Health & Medicine
Marijuana Legalization Link to Fewer Workers' Compensation Claims
FEB 25, 2021
Marijuana Legalization Link to Fewer Workers' Compensation Claims
A new paper produced partially under the auspices of the federal government and published by the National Bureau of Econ ...
Loading Comments...